Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/IIa Study of Cabazitaxel plus Bavituximab in patients with
castration-resistant prostate cancer (CRPC). The current study is designed to determine if
the addition of bavituximab to cabazitaxel will improve progression free survival (PFS) or
overall survival (OS). In addition, the Lead Researcher is requiring the collection of urine,
and blood specimens for future research.
This study will enroll patients with CRPC, who have been previously treated with docetaxel or
a docetaxel-containing regimen. Patients may be intolerant of, or resistant to, docetaxel, or
may have been previously treated with the agent without definite disease progression during
therapy.
Patients must meet the study eligibility criteria and must be competent to give informed
consent.